How Do Bempedoic Acid Impurity 1 and Impurity 2 Influence Drug Stability?
Pharmaceutical material can be no better than its purity permits it to be. This is particularly the case with Bempedoic Acid, a new lipid-lowering agent that poses an alternative option to statins. While the active pharma ingredient functions as designed, the overall performance is highly dependent on trace-level contaminant presence. Trivial amounts can result in shortened shelf life, diminished therapeutic effect, or failure in auditing procedures with the regulating bodies.
Two of the significant degradation products, such as Bempedoic Acid Impurity 1 (CAS No. 738606-43-4) and Bempedoic Acid Impurity 2 (CAS No. 738606-64-9), are crucial for the long-term stability profile of the drug. These compounds are not just by-products. They’re indicators of how well the formulation will hold up during manufacturing, transit, and storage. For that reason, their stress behaviour must be well comprehended and proactively controlled.
What is Bempedoic Acid?
Bempedoic Acid is an ATP-citrate lyase inhibitor, which is frequently prescribed for treating hypercholesterolemia. Its action focuses on the biosynthesis of cholesterol within the liver, thereby decreasing LDL cholesterol.
Due to its chemical constitution, notably the presence of ester and carboxylic groups, receptors are sensitive to environmental influences. The effect of heat, humidity, and oxidation can invoke chemical degradation and therefore produce impurities that can travel and alter the performance of the actinomers themselves.
Chemical Profiles of the Impurities
Category: Impurity Standards
Subcategory: Bempedoic Acid
CAS No.: 738606-43-4
Structure: Diethyl 2,2,14,14-tetramethyl-8-oxopentadecanedioate
Molecular Formula: C23H42O5
Impact: Often appears due to oxidative degradation during storage or synthesis.
CAS No.: 738606-64-9
Structure: Diethyl 8-hydroxy-2,2,14,14-tetramethylpentadecanedioate
Molecular Formula: C23H44O5
Impact: Forms primarily via hydrolysis under high-humidity or extreme pH conditions.
Both impurities can affect the drug’s stability by disrupting its chemical composition or interacting with excipients and packaging materials.
Deterioration Initiators and Storage Effect
Several studies attest that Bempedoic Acid degrades under the following circumstances:
This evidence directly verifies that stress from the environment pushes the formation of impurities. That's why temperature and humidity have to be accurately controlled at storage (ideally 2–8°C). Storing away from light and oxygen also minimises oxidative breakdown.
Manufacturing and Quality Control Measures
It is not enough to detect impurities after they appear. Proactive steps must be taken during production to limit their formation:
Conclusion
In-depth knowledge of Bempedoic Acid Impurity 1 (CAS No. 738606-43-4) and Impurity 2 (CAS No. 738606-64-9) enables pharma companies to develop products that sustain stability, safety, and efficacy over a period of time. Failure of proper impurity profiling and controls can destroy the clinical utility of the drug, though it has an established therapeutic role.
For authentic standards and reference materials on reliability for impurities, Chemicea is the global pharma's trusted partner. The company is ISO and GMP certified and supplies over 2000+ customers across 35+ international destinations. They guarantee that each and every material meets the stringent regulatory requirements.
Get in Touch with Chemicea today and obtain your Bempedoic Acid impurity standards and move that step closer towards regulatory-compliant, high-quality preparations.